Pseudomonas aeruginosa is a Gram-negative strict aerobic Bacillus that causes around 10% of nosocomial infections. This bacillus can become resistant to multiple antibiotics, and it has been described mainly in inmuno compromised patients. The prevalence of multidrug resistant Pseudomonas has been increasing over the last few years. Currently we have new agents to treat this type of infection. Doripenem is the new B-lactam from the carbapenem family, which has demonstrated in vitro the best activity against multidrug resistant Pseudomonas aeruginosa in different studies. Its mechanism of action consists of the inactivation of penicillin-binding proteins in the cell wall. This agent has been indicated in the treatment of several infections, such as complicated intraabdominal infections, complicated urinary tract infections and nosocomial pneumonia. The principal difference between doripenem and the other carbapenems, is the capacity of preventing the generation of resistant strains of Pseudomonas aeruginosa, so it is especially useful for severe infections caused by multidrug resistant Pseudomonas aeruginosa. But this situation may change if we don't use antibiotics properly. Promoting rationale use of antibiotics to treat infections caused by Pseudomonas aeruginosa may be critical to make the emergence of multidrug resistant strains difficult. The present review describes the main features of doripenem and its potential role in managing infections due to multi-drug resistant Pseudomonas aeruginosa.